{"filings":[{"id":1176877,"accession_number":"0001104659-26-076067","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-06-22T11:11:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbbVie to acquire Apogee Therapeutics for $10.9B; adds zumilokibart pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total equity value ~$10.9 billion, AbbVie to pay $135.11 per share in cash for all outstanding shares.","Apogee lead asset zumilokibart (APG777) is a half-life extended anti-IL-13 antibody for atopic dermatitis and asthma.","Transaction expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.","Deal projected to be accretive to AbbVie adjusted diluted EPS beginning 2032; key shareholders support.","AbbVie will host an investor conference call on June 22 at 8:00 a.m. CT to discuss the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42443,"accession_number":"0001104659-26-059484","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-05-12T21:01:51+00:00","items":["5.07"],"status":"ready","headline":"AbbVie shareholders re-elect all Class II directors; reject supermajority elimination and independent chair proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class II directors elected: Davis (1.22B for), Meyer (1.28B), Michael (1.22B), Waddell (1.23B).","Ratification of EY as auditor approved with 1.52B votes for, 23.8M against.","Advisory say-on-pay approved with 1.23B for, 69.3M against.","Proposal to eliminate supermajority voting did not pass: 1.29B for (needed supermajority).","Stockholder proposal for independent chair rejected: 515.6M for, 787.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93577,"accession_number":"0001551152-26-000013","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q1 adjusted EPS $2.65 (+7.7%), revenue $15.0B (+12.4%); raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.39, down 45.8%; adjusted EPS $2.65, up 7.7%, with $0.41 IPR&D headwind.","Net revenue $15.002B, +12.4% reported / +10.3% operational; immunology portfolio $7.290B (+16.4%).","Skyrizi $4.483B (+30.9%), Rinvoq $2.119B (+23.3%), Humira $688M (-38.6%); neuroscience +26%.","FY2026 adjusted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16.","FDA CRL for trenibotulinumtoxinE on manufacturing; no safety/efficacy issues; expects prompt refiling."],"consensus_eps_estimate":2.6452,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":15002000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93576,"accession_number":"0001551152-26-000011","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie records $744M IPR&D expense in Q1; cuts adjusted EPS guidance by $0.41","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 includes $744M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.41.","Updated Q1 adjusted EPS guidance: $2.56-$2.60 (from $2.97-$3.01, excluding Q1 IPR&D).","Full-year 2026 adjusted EPS guidance lowered to $13.96-$14.16 (from $14.37-$14.57).","Company states future IPR&D milestones cannot be reliably forecasted; guidance excludes them beyond Q1.","Adjusted diluted EPS guidance now includes impact of Q1 expense; prior range excluded it."],"consensus_eps_estimate":2.6452,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":15002000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105323,"accession_number":"0001104659-26-023534","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbbVie closes $7.75B debt offering across seven tranches (2028-2066)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed public offering of $750M floating rate notes due 2028 and $7B in fixed rate notes (3.775% to 5.650%) maturing 2028-2066.","Largest tranches: $1.5B of 3.775% notes due 2028 and $1.5B of 4.750% notes due 2036.","Longest maturity: $500M of 5.650% senior notes due 2066.","Notes are unsecured, unsubordinated, and rank equally with existing unsecured debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105322,"accession_number":"0001104659-26-020643","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbbVie prices $8B multi-tranche senior note offering; net proceeds ~$7.95B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $8.0B in senior notes across seven tranches (2028–2066), rates from floating to 5.650%.","Net proceeds ~$7.95B; $2B to repay outstanding term loan due May 2026; remainder for general corporate purposes.","Underwriting syndicate led by J.P. Morgan, BofA, Morgan Stanley, Wells Fargo; closing expected March 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105321,"accession_number":"0001551152-26-000004","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q4 revenue $16.6B (+10%); FY2025 adj EPS $10.00; guides FY2026 adj EPS $14.37-$14.57","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $61.160B (+8.6% reported); GAAP diluted EPS $2.36; adjusted diluted EPS $10.00 (-1.2% YoY).","Q4 revenue $16.618B (+10% reported); GAAP EPS $1.02; adjusted EPS $2.71; includes $0.71 IPR&D hit.","Immunology portfolio grew 14% in FY2025; Skyrizi $17.562B, Rinvoq $8.304B; Humira fell to $4.540B.","FY2026 adjusted EPS guidance $14.37-$14.57, excluding future IPR&D and milestones expense.","Announced voluntary pricing agreement with Trump admin; $100B U.S. R&D/capex over 10 years."],"consensus_eps_estimate":2.7053,"consensus_eps_actual":2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":61160000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105320,"accession_number":"0001551152-26-000002","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie cuts Q4 2025 adjusted EPS guidance by $0.71 on $1.265B IPR&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 adjusted EPS guidance revised to $2.61-$2.65 from prior $3.32-$3.36.","Full-year 2025 adjusted EPS guidance lowered to $9.90-$9.94 from $10.61-$10.65.","Pre-tax acquired IPR&D and milestones expense of $1,265M (unfavorable $0.71 to GAAP and adjusted EPS).","Q4 2025 results not finalized; expense relates to collaborations and licensing deals.","AbbVie does not forecast IPR&D/milestones expense due to uncertainty."],"consensus_eps_estimate":2.7053,"consensus_eps_actual":2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":61160000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121602,"accession_number":"0001551152-25-000047","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q3 adjusted EPS $1.86 (down 38%), revenue up 9.1%; raises FY25 guidance; dividend up 5.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.10 (down 88.6%); adjusted diluted EPS $1.86 (down 38%); includes $1.50/share unfavorable impact from acquired IPR&D.","Net revenues $15.776B, up 9.1% reported (8.4% operational); Immunology $7.885B (+11.9%) led by Skyrizi $4.708B (+46.8%).","Raises 2025 adjusted diluted EPS guidance to $10.61-$10.65 (from $10.38-$10.58); includes $2.05/share YTD IPR&D impact.","Quarterly dividend increased 5.5% to $1.73/share, payable Feb 17, 2026 to holders of record Jan 16, 2026.","Oncology $1.682B (-0.3%); Aesthetics $1.193B (-3.7%); Neuroscience $2.841B (+20.2%); Vraylar $934M, Botox Therapeutic $985M."],"consensus_eps_estimate":1.8103,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":44542000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121601,"accession_number":"0001551152-25-000043","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie cuts FY 2025 adjusted EPS guidance to $10.38-$10.58 on $2.68B Q3 IPR&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 acquired IPR&D and milestones expense of $2.68B reduces adjusted EPS by $1.50.","Q3 2025 adjusted EPS guidance revised to $1.74-$1.78 from prior $3.24-$3.28.","Full-year 2025 adjusted EPS guidance lowered to $10.38-$10.58 from $11.88-$12.08.","Previously announced FY guidance excluded Q3 IPR&D; further IPR&D beyond Q3 not forecasted.","Q3 results not finalized; preliminary estimates subject to closing procedures."],"consensus_eps_estimate":1.8103,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":44542000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138258,"accession_number":"0001104659-25-089245","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbbVie settles RINVOQ patent litigation; no generic entry until at least April 2037","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settled litigation with all generic manufacturers over RINVOQ (upadacitinib) ANDAs.","No generic entry expected before April 2037 in the US, assuming pediatric exclusivity.","Extends AbbVie's market exclusivity for RINVOQ, a key immunology drug.","Settlement and license agreements subject to standard acceleration provisions.","Removes a significant overhang for AbbVie's revenue stream."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138257,"accession_number":"0001551152-25-000036","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q2 adjusted EPS $2.97 (+12.1%); raises FY 2025 guidance to $11.88-$12.08","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP EPS $0.52 (down 32.5%); adjusted EPS $2.97 (+12.1%); revenue $15.423B (+6.6%).","Immunology revenue $7.631B (+9.5%); Skyrizi $4.423B (+62.2%), Rinvoq $2.028B (+41.8%), Humira $1.180B (-58.1%).","FY 2025 adjusted EPS guidance raised from $11.67-$11.87 to $11.88-$12.08; includes $0.55 IPR&D impact.","Agreed to acquire Capstan Therapeutics (anti-CD19 CAR-T for autoimmune diseases); terms not disclosed.","FDA approved Rinvoq for giant cell arteritis; Emrelis accelerated approval for c-Met high NSCLC."],"consensus_eps_estimate":2.9421,"consensus_eps_actual":1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":28766000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138256,"accession_number":"0001551152-25-000034","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie expects Q2 2025 acquired IPR&D expense of $823M, lowers adjusted EPS guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Acquired IPR&D and milestones expense of $823M pre-tax in Q2 2025 reduces GAAP and adjusted EPS by $0.42.","Full-year 2025 adjusted diluted EPS guidance range lowered to $11.67-$11.87 from $12.09-$12.29.","Q2 2025 adjusted diluted EPS guidance range now $2.84-$2.88 versus prior $3.26-$3.30.","Guidance excludes any acquired IPR&D expense beyond Q2 2025 due to forecasting uncertainty.","Q2 2025 results are preliminary and subject to financial statement closing procedures."],"consensus_eps_estimate":2.9421,"consensus_eps_actual":1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":28766000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155712,"accession_number":"0001104659-25-047402","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AbbVie appoints Thomas Falk (ex-Kimberly-Clark CEO) to board; Gonzalez, Tilton to retire July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 15; Thomas J. Falk (former Kimberly-Clark CEO) appointed as Class III director and to Audit Committee; deemed independent.","Board to shrink to 13 upon retirement of Richard A. Gonzalez and Glenn F. Tilton effective July 1, 2025.","Compensation Committee raised Robert A. Michael's 2025 annual bonus target to 165% of base salary for Chairman role.","Shareholders ratified EY as auditor and approved say-on-pay; both management and stockholder proposals to eliminate supermajority voting failed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155711,"accession_number":"0001551152-25-000026","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q1 adj EPS $2.46 (+6.5%), revenue $13.34B (+8.4%); raises FY EPS guidance to $12.09-$12.29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.72 (down 6.5%), adjusted EPS $2.46 (up 6.5%); revenue $13.34B (+8.4% reported).","Immunology growth: Skyrizi $3.43B (+70.5%), Rinvoq $1.72B (+57.2%); Humira $1.12B (-50.6%).","Aesthetics down 11.7% to $1.10B; Botox Cosmetic -12.3%, Juvederm -22.2%.","FY2025 adjusted diluted EPS guidance raised to $12.09-$12.29 from $11.99-$12.19.","CEO Robert A. Michael elected chairman effective July 1, 2025, succeeding Richard A. Gonzalez."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":13343000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155710,"accession_number":"0001551152-25-000023","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie revises FY 2025 adj. EPS guidance down $0.13 on $248M IPR&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 includes $248M pre-tax acquired IPR&D and milestones expense.","Q1 2025 adjusted diluted EPS guidance: $2.34-$2.38 (prior $2.47-$2.51).","Full-year 2025 adjusted diluted EPS guidance: $11.99-$12.19 (from $12.12-$12.32).","Revised guidance excludes AbbVie-Gubra GUB014295 licensing deal closed after Q1.","Company does not forecast future IPR&D milestones due to uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":13343000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174204,"accession_number":"0001104659-25-017490","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbbVie closes $4.0B senior notes offering across four maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $4.0B debt offering: $1.25B 4.650% notes due 2028, $1B 4.875% notes due 2030, $1B 5.200% notes due 2035, $750M 5.600% notes due 2055.","Notes are unsecured, unsubordinated obligations ranking equally with existing and future unsecured debt.","AbbVie may redeem notes at par after certain dates: 2028 notes after Feb 15, 2028; 2030 after Feb 15, 2030; 2035 after Dec 15, 2034; 2055 after Sep 15, 2054.","Proceeds not specified; offering registered under Form S-3ASR filed Feb 14, 2025, prospectus supplement dated Feb 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174203,"accession_number":"0001104659-25-015015","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbbVie issues $4B in senior notes across four maturities to refinance near-term debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.25B 4.650% notes due 2028, $1B 4.875% due 2030, $1B 5.200% due 2035, $750M 5.600% due 2055.","Net proceeds ~$3.98B after underwriting discounts and expenses.","Proceeds plus cash on hand to repurchase or repay $3.75B 3.600% notes due May 2025 and/or $2.89B 3.800% notes due March 2025.","Closing expected February 26, 2025; underwriters include BofA, J.P. Morgan, Morgan Stanley, Barclays, Mizuho.","Offering also includes refinancing of $130M Allergan Funding 3.800% notes due March 2025 or general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174202,"accession_number":"0001104659-25-013467","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AbbVie appoints CEO Robert Michael as Chairman, Gonzalez to retire July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Robert A. Michael unanimously elected Chairman, effective July 1, 2025.","Chairman Richard A. Gonzalez retires from board effective July 1, 2025; served as Chairman since AbbVie's 2013 formation.","Director Glenn F. Tilton also retires from board effective July 1, 2025; lead independent director from 2013 to 2024.","Michael continues as CEO and assumes additional role of Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174201,"accession_number":"0001104659-25-009673","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbbVie enters $3.0 billion revolving credit facility maturing in 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On January 30, 2025, AbbVie entered a $3.0 billion unsecured revolving credit agreement with JPMorgan Chase as agent.","The new facility matures on January 30, 2030, and AbbVie had no borrowings outstanding on the effective date.","AbbVie's existing $5.0 billion revolver maturing in March 2028 remains in effect, bringing total revolving capacity to $8.0 billion.","Borrowings under the facility bear variable interest rates and are subject to customary covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174200,"accession_number":"0001551152-25-000011","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q4 GAAP loss $0.02 (emraclidine impairment), adj. EPS $2.16; FY rev $56.3B, 2025 adj. EPS guide $12.12-12.32","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $15.102B (+5.6% reported); full-year revenue $56.334B (+3.7% reported).","Q4 GAAP diluted loss per share $0.02 (includes $3.5B impairment for emraclidine); adjusted diluted EPS $2.16.","Global Skyrizi revenue $3.778B (+57.7%) in Q4; Rinvoq revenue $1.834B (+46.2%); Humira revenue -49.1% to $1.682B.","2025 adjusted EPS guidance $12.12-$12.32; raises 2027 Skyrizi+Rinvoq revenue outlook to >$31B.","Full-year immunology revenue $26.682B (+2.1%); neuroscience $8.999B (+16.6%); aesthetics $5.176B (-2.2%)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":56334000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174199,"accession_number":"0001551152-25-000006","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.06"],"status":"ready","headline":"AbbVie to record $3.5B impairment on emraclidine after Phase 2 schizophrenia failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-cash after-tax impairment charge of ~$3.5B on emraclidine intangible asset from Cerevel acquisition.","Two Phase 2 EMPOWER trials failed to meet primary endpoint: no significant reduction in PANSS total score vs placebo at week 6.","Remaining Cerevel-related intangible assets of ~$3.6B continue to be evaluated for potential impairment.","Impairment reflects significant decrease in estimated future cash flows for emraclidine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174198,"accession_number":"0001551152-25-000002","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie reports $1.574B Q4 IPR&D charge, cuts adjusted EPS guidance by $0.88","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expected Q4 2024 acquired IPR&D and milestones expense of $1,574M pre-tax, $0.88 per share impact.","Adjusted diluted EPS guidance for Q4 2024 revised to $2.06-$2.10 (from $2.94-$2.98).","Full-year 2024 adjusted diluted EPS guidance revised to $10.02-$10.06 (from $10.90-$10.94).","Previous guidance excluded Q4 IPR&D expense; company does not forecast such expenses.","Q4 2024 results not finalized; subject to closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191138,"accession_number":"0001104659-24-128413","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AbbVie controller Buckbee retiring March 1, 2025; Purdue named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin K. Buckbee, Senior Vice President, Controller, to retire effective March 1, 2025.","David R. Purdue appointed Senior Vice President, Controller effective March 1, 2025.","Purdue currently VP Controller, Commercial Operations; joined Abbott in 2003.","Purdue's annual base salary set at $550,000; target bonus 85% of salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191137,"accession_number":"0001551152-24-000036","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q3 EPS $3.00 adjusted (+1.7%), revenue $14.46B (+3.8%); raises 2024 guidance, increases dividend 5.8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted diluted EPS $3.00, up 1.7% YoY; GAAP EPS $0.88, down 12.0%.","Revenue $14.460B, +3.8% reported (+4.9% operational); Immunology $7.046B (+3.9%) led by Skyrizi (+50.8%) and Rinvoq (+45.3%).","Raises 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87.","Increases quarterly dividend 5.8% to $1.64/share, payable Feb 14, 2025 to holders of record Jan 15, 2025.","Completed acquisition of Cerevel, adding pipeline of complementary neuroscience assets."],"consensus_eps_estimate":null,"consensus_eps_actual":2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":41232000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191136,"accession_number":"0001551152-24-000033","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie cuts 2024 adjusted EPS guidance by $0.04 on $82M Q3 IPR&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 acquired IPR&D & milestones expense of $82M pre-tax, reducing GAAP and adjusted EPS by $0.04.","Q3 2024 adjusted diluted EPS guidance range now $2.88–$2.92, including the charge.","Full-year 2024 adjusted diluted EPS guidance revised to $10.67–$10.87 from $10.71–$10.91.","Guidance excludes any IPR&D expense beyond Q3 2024 due to forecasting uncertainty.","Q3 2024 results are preliminary and subject to final closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":41232000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207614,"accession_number":"0001104659-24-098564","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"AbbVie amends bylaws, deletes section 2.13(D)(iv) amid stockholder class action","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Third Amended and Restated By-laws effective September 6, 2024.","Amendments update registered agent address and delete Section 2.13(D)(iv) in its entirety.","Company is defendant in a stockholder class action challenging Section 2.13(D)(iv).","Company believes provision lawful but no longer of practical value; deletion avoids defending it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207613,"accession_number":"0001551152-24-000026","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q2 adj EPS $2.65, revenue $14.46B; raises FY2024 adj EPS guidance to $10.71-$10.91","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP EPS $0.77 (down 32.5% YoY); adjusted EPS $2.65 (down 8.9% YoY), including $0.52 IPR&D impact.","Net revenue $14.462B (+4.3% reported, +5.6% operational); Immunology up 2.3% as Humira -29.8% offset by Skyrizi +44.8% and Rinvoq +55.8%.","Neuroscience portfolio up 14.7% to $2.162B; Aesthetics flat at $1.390B.","FY2024 adjusted EPS guidance raised to $10.71-$10.91 from $10.61-$10.81, including $0.60 IPR&D impact.","Recent events: Robert Michael became CEO July 1; FDA approved Skyrizi for UC; FDA CRL for ABBV-951 Parkinson's; acquisitions of Landos and Celsius."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":26772000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207612,"accession_number":"0001551152-24-000024","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie lowers 2024 adjusted EPS guidance to $10.61-$10.81 on $937M IPR&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2024 acquired IPR&D and milestones expense of $937 million pre-tax.","GAAP and adjusted non-GAAP diluted EPS each reduced by $0.52 in Q2.","Q2 2024 adjusted diluted EPS guidance set at $2.53-$2.57.","Full-year 2024 adjusted diluted EPS guidance lowered to $10.61-$10.81 from $11.13-$11.33.","Guidance excludes any future IPR&D expense beyond Q2; final Q2 results subject to closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":26772000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225063,"accession_number":"0001104659-24-058808","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K/A","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AbbVie approves CEO compensation for Robert Michael; shareholders reject supermajority repeal","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO-elect Robert Michael base salary set at $1.7M with target bonus of 150% of base, effective July 1, 2024.","Outgoing CEO Richard Gonzalez receives $1.5M base salary as Executive Chairman, target bonus 140% of base.","Shareholders approved all directors and say-on-pay advisory vote (annual basis) with majority support.","Proposal to eliminate supermajority voting failed with 1.249B for, 21.4M against, but required supermajority not met.","Stockholder proposals on simple majority voting, lobbying report, and patent report all rejected with over 900M against each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225065,"accession_number":"0001551152-24-000016","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q1 adjusted EPS $2.31 (-6.1% YoY); raises 2024 guidance; CEO succession","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $12.31B (+0.7% reported, +1.6% operational); GAAP EPS $0.77, adjusted EPS $2.31.","Immunology revenue $5.371B (-3.9%) on Humira erosion; Skyrizi +47.6%, Rinvoq +59.3%.","Oncology +9% to $1.543B; Neuroscience +15.9% to $1.965B; Aesthetics -4% to $1.249B.","Raises 2024 adjusted EPS guidance to $11.13-$11.33 from $10.97-$11.17; includes $0.08 IPR&D impact.","CEO succession: Robert Michael to become CEO July 1; Richard Gonzalez becomes executive chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":12310000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225064,"accession_number":"0001551152-24-000013","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie updates 2024 EPS guidance after incurring $164M IPR&D expense in Q1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Acquired IPR&D and milestones expense of $164M pre-tax ($0.08 per share) recorded in Q1 2024.","Q1 2024 adjusted diluted EPS guidance revised to $2.18-$2.22 from $2.26-$2.30 previously.","Full-year 2024 adjusted diluted EPS guidance revised to $10.97-$11.17 from $11.05-$11.25.","Future IPR&D and milestones expense excluded from guidance due to unpredictable deal timing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":12310000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244290,"accession_number":"0001104659-24-027585","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AbbVie issues $15B in senior notes across 7 tranches to fund acquisitions and repay debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $15.0B aggregate principal of senior notes maturing 2027-2064 with coupons from 4.800% to 5.500%.","Proceeds will prepay $5.0B term loan used for ImmunoGen acquisition and fund pending Cerevel acquisition.","Notes are unsecured, unsubordinated obligations ranking equally with existing unsecured indebtedness.","Underwriters include Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244289,"accession_number":"0001104659-24-025262","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AbbVie names Robert Michael as CEO effective July 1; Gonzalez to executive chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert A. Michael, current president & COO, will become CEO on July 1, 2024.","Richard A. Gonzalez retires as CEO after 11 years, becomes executive chairman.","Michael appointed to board as Class II director, effective July 1, 2024.","Gonzalez to remain as executive chairman; board conducted thorough succession process.","Michael played key role in Allergan, ImmunoGen, and pending Cerevel acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244288,"accession_number":"0001104659-24-013692","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbbVie completes $31.26/share ImmunoGen acquisition; reaffirms FY2024 EPS guidance with $0.42 dilution","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all outstanding ImmunoGen shares for $31.26 each; ImmunoGen ceases trading on NASDAQ.","Adds ELAHERE (FRα-positive ovarian cancer ADC) and pipeline assets including IMGN-151 and pivekimab sunirine.","Reaffirms full-year 2024 adjusted diluted EPS guidance of $11.05-$11.25, now including $0.42 dilution from ImmunoGen and pending Cerevel.","Updates Q1 2024 adjusted EPS guidance to $2.26-$2.30 from $2.30-$2.34 due to $0.04 dilutive impact from ImmunoGen.","Expects the acquisition to be accretive to diluted EPS beginning in 2027 and significantly accretive over long term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244287,"accession_number":"0001551152-24-000007","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q4 adj. EPS $2.79, revenue $14.3B; FY2024 adj. EPS guidance $11.05-$11.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 GAAP EPS $2.72 (-59%); adjusted EPS $11.11 (-19.3%); revenue $54.3B (-6.4%).","Q4 2023 GAAP EPS $0.46 (-66.7%); adjusted EPS $2.79 (-22.5%); revenue $14.3B (-5.4%).","Humira Q4 revenue $3.3B (-40.8% on biosimilar competition); Skyrizi up 51.9%; Rinvoq up 62.9%.","Announced ImmunoGen acquisition (~$10.1B equity) and Cerevel (~$8.7B); expected close mid-2024.","FY2024 adj. EPS guidance $11.05-$11.25 includes $0.32 dilution from pending deals; long-term CAGR reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":2.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":54318000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244286,"accession_number":"0001551152-24-000002","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie updates Q4 and FY 2023 adjusted EPS guidance for $282M IPR&D expense","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 acquired IPR&D and milestones expense of $282M pre-tax reduces GAAP and adjusted EPS by $0.15.","Updated Q4 2023 adjusted diluted EPS guidance range: $2.72 - $2.76 (prior $2.87 - $2.91).","Full-year 2023 adjusted diluted EPS guidance now $11.04 - $11.08 (prior $11.19 - $11.23).","Full-year 2023 acquired IPR&D and milestones expense totals $778M.","AbbVie notes these expenses are inherently unforecastable; final Q4 results may differ."],"consensus_eps_estimate":null,"consensus_eps_actual":2.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":54318000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261705,"accession_number":"0001104659-23-124047","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbbVie to acquire Cerevel Therapeutics for $45/share (~$8.7B equity value)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction valued at $45.00 per Cerevel share, total equity ~$8.7B; approved by both boards.","Cerevel's late-stage asset emraclidine is a potential best-in-class antipsychotic for schizophrenia.","Deal expected to close mid-2024, subject to Cerevel shareholder vote, regulatory approvals, and customary conditions.","Acquisition adds multiple clinical assets: tavapadon (Parkinson's), CVL-354 (MDD), darigabat (epilepsy/panic).","AbbVie expects transaction to be accretive to adjusted diluted EPS beginning in 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261704,"accession_number":"0001104659-23-122241","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AbbVie to acquire ImmunoGen for $31.26/share ($10.1B total) – adds ovarian cancer therapy ELAHERE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction valued at $31.26 per share in cash, total equity value approx $10.1B.","Premium of ~95% to ImmunoGen's closing price on Nov 29, 2023.","Expected to close mid-2024; negatively impact 2024 EPS by ~$0.13, 2025 by ~$0.16, accretive from 2027.","Key asset: ELAHERE, a first-in-class ADC approved for platinum-resistant ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261703,"accession_number":"0001551152-23-000040","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q3 adj EPS $2.95 (down 19.4%); raises FY23 and FY24 guidance; dividend up 4.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP diluted EPS $1.00 (down 54.8% YoY); adjusted diluted EPS $2.95 (down 19.4%); net rev $13.93B (down 6.0%).","Immunology down 11.3% as Humira fell 36.2%; Skyrizi up 52.1% and Rinvoq up 59.8% drove growth in other segments.","Raises 2023 adj EPS guidance to $11.19-$11.23 from $10.86-$11.06; 2024 floor raised to $11.00 from $10.70.","Dividend increased 4.7% to $1.55/quarter; payable Feb 15, 2024 to holders of record Jan 16, 2024.","Records $2.1B pre-tax impairment on Imbruvica intangible due to IRA price negotiation; remaining carrying value $1.8B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":40017000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261702,"accession_number":"0001104659-23-108864","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AbbVie expands board to 13, appoints Jennifer Davis and Susan Quaggin as directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 11 to 13 directors; Jennifer Davis (Class II) and Susan Quaggin (Class III) appointed.","Davis is CEO, Health Care at Procter & Gamble; Quaggin is Irving S. Cutter Professor and Chair of Medicine at Northwestern.","Davis appointed to Nominations and Governance Committee; Quaggin to Public Policy and Sustainability Committee.","Board affirmatively determined both are independent under NYSE standards and AbbVie guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261701,"accession_number":"0001551152-23-000036","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie updates 2023 EPS guidance to include $66M acquired IPR&D expense","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 acquired IPR&D & milestones expense of $66M pre-tax; reduces diluted EPS by $0.04.","Updated Q3 2023 adjusted diluted EPS guidance: $2.76 - $2.86 (previously $2.80 - $2.90).","Full-year 2023 adjusted diluted EPS guidance: $10.86 - $11.06 (previously $10.90 - $11.10).","Prior guidance excluded Q3 2023 IPR&D expense; company does not forecast such expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":40017000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278919,"accession_number":"0001551152-23-000028","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q2 adj EPS $2.91 (-13.6%), rev $13.865B (-4.9%); raises FY adj EPS guidance to $10.90-$11.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.14 (+123.5% YoY); adjusted diluted EPS $2.91 (-13.6% YoY); includes $0.15 IPR&D impact.","Total net revenues $13.865B (-4.9% reported; -4.2% operational). Immunology $6.813B (-5.5%); Humira -25.2% to $4.012B.","Skyrizi +50.4% to $1.883B; Rinvoq +55.1% to $918M. Neuroscience +13.6% to $1.885B; Vraylar +33.9%.","Raised FY2023 adjusted diluted EPS guidance from $10.57-$10.97 to $10.90-$11.10; includes $0.23 IPR&D year-to-date."],"consensus_eps_estimate":null,"consensus_eps_actual":1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":26090000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278918,"accession_number":"0001551152-23-000026","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie lowers 2023 adjusted EPS guidance to $10.57-$10.97 on $280M Q2 IPR&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 includes $280M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.15.","Full-year 2023 adjusted diluted EPS guidance reduced to $10.57-$10.97 from $10.72-$11.12.","Q2 2023 adjusted diluted EPS guidance now $2.75-$2.85, down from $2.90-$3.00 prior.","Company does not forecast further IPR&D expense beyond Q2 due to uncertainty of timing.","Charge stems from collaborations, licensing agreements, and other asset acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":26090000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297201,"accession_number":"0001104659-23-076373","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AbbVie appoints Robert A. Michael as President and COO effective June 29, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert A. Michael appointed President and Chief Operating Officer effective June 29, 2023.","He will continue oversight of AbbVie's global commercial and financial operations.","New responsibilities include operations, human resources, business development, and corporate strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297200,"accession_number":"0001104659-23-058520","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AbbVie shareholders elect directors, ratify auditor, approve say-on-pay; supermajority amendment fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors Alpern, Meyer, Waddell elected with 1.14B, 1.25B, and 1.21B votes respectively.","Shareholders ratified Ernst & Young as auditor for 2023 with 1.49B votes for vs 18.7M against.","Advisory vote on executive compensation passed with 1.14B for vs 109.3M against.","Management proposal to eliminate supermajority voting failed (1.24B for, 1.29M against; needed supermajority).","Stockholder proposal for simple majority voting approved with 668.5M for vs 581.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297199,"accession_number":"0001551152-23-000019","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie Q1 revenue $12.2B down 9.7%; GAAP EPS $0.13, adj. EPS $2.46; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenues $12.225B, down 9.7% reported / 8.3% operational; GAAP diluted EPS $0.13 (down 94.8%), adj. diluted EPS $2.46 (down 22.2%).","Immunology portfolio $5.587B (-9%); Humira $3.541B (-25.2%), Skyrizi $1.360B (+44.7%), Rinvoq $686M (+47.5%).","Hematologic oncology $1.416B (-14%); Imbruvica $878M (-25.2%), Venclexta $538M (+13.7%).","Raises FY 2023 adj. diluted EPS guidance from $10.62-$11.02 to $10.72-$11.12.","Neuroscience $1.695B (+13.9%); aesthetics $1.300B (-5.4%)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":12225000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297198,"accession_number":"0001551152-23-000015","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie lowers 2023 adjusted EPS guidance by $0.08 on $150M Q1 IPR&D expense","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 acquired IPR&D and milestones expense of $150M pre-tax reduces GAAP and adjusted EPS by $0.08.","Q1 2023 adjusted diluted EPS guidance lowered to $2.31-$2.41 from $2.39-$2.49.","Full-year 2023 adjusted diluted EPS guidance lowered to $10.62-$11.02 from $10.70-$11.10.","Company does not forecast future IPR&D and milestones expense; guidance excludes any beyond Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":12225000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317576,"accession_number":"0001104659-23-037749","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AbbVie amends revolver: commitments raised to $5.0B, maturity extended to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility commitments increased from $4.0B to $5.0B.","Maturity date extended from August 27, 2024 to March 28, 2028.","Facility remains unsecured; JPMorgan Chase continues as administrative agent.","Second Amended and Restated Revolving Credit Agreement dated March 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317575,"accession_number":"0001551152-23-000006","cik":1551152,"company_name":"AbbVie Inc.","ticker":"ABBV","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AbbVie reports FY 2022 adjusted EPS $13.77 (+16.4% YoY); guides FY 2023 adjusted EPS $10.70-$11.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2022 net revenues $58.054B (+3.3% reported, +5.1% operational); Q4 net revenues $15.121B (+1.6% reported, +3.8% operational).","GAAP diluted EPS FY $6.63 (+2.8%); adjusted diluted EPS $13.77 (+16.4%). Q4 GAAP diluted EPS $1.38 (-38.9%); adjusted $3.60 (+16.9%).","Immunology portfolio FY net revenues $28.924B (+14.4%); Humira $21.237B, Skyrizi $5.165B, Rinvoq $2.522B.","Hematologic oncology portfolio FY net revenues $6.577B (-9.0%); Imbruvica $4.568B, Venclexta $2.009B.","2023 adjusted diluted EPS guidance $10.70-$11.10 (excludes IPR&D and milestones); management cites U.S. Humira LOE as headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":6.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":58054000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":385487686329.57446,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-09T23:59:59+00:00|317575"}